1. A method of treating a patient suffering from a pathogenic endobronchial microbial infection, comprising administering to the patient a therapeutically effective amount of an antibacterial monobactam compound, or a pharmaceutically acceptable salt or prodrug thereof, and administering to the patient an amount of a mucolytic agent effective to enhance the antibacterial activity of the monobactam compound in the endobronchial space of the patient.
2. A method of claim 1 wherein the monobactam compound is 2R 2\u03b1, 3\u03b1(Z)-3-1 (2 amino-4-thiazolyl)-2 (2 methyl 4-oxo-1 sulfo-3 azetidinyl)amino-2 oxoethylideneaminooxymethyl-6,7-dihydroxy-2-quinoxalinecarboxylic acid, aztreonam or carumonam, or a pharmaceutically acceptable salt or prodrug thereof.
3. A method of claim 1 wherein the mucolytic agent is selected from the group consisting of N-acetyl-L-cysteine, recombinant human Dnase, Erdosteine, Gauifenesin, and sodium taurocholate.
4. A method of claim 1 wherein the mucolytic agent is administered to the patient prior to administration of the monobactam compound.
5. A method for inhibiting the growth of susceptible microbes in the presence of mucin by treating the microbes with a antibacterially effective amount of an monobactam compound, or a pharmaceutically acceptable salt or prodrug thereof, and with an amount of a mucolytic agent effective to enhance the antibacterial activity of the monobactam compound
6. A method of claim 5 wherein the monobactam compound is 2R 2\u03b1, 3\u03b1(Z)-3-1 (2 amino-4-thiazolyl)-2 (2 methyl 4-oxo-1 sulfo-3 azetidinyl)amino-2 oxoethylideneaminooxymethyl-6,7-dihydroxy-2-quinoxalinecarboxylic acid, aztreonam or carumonam, or a pharmaceutically acceptable salt or prodrug thereof.
7. A method of claim 5 wherein the mucolytic agent is selected from the group consisting of N-acetyl-L-cysteine, recombinant human Dnase, Erdosteine, Gauifenesin, and sodium taurocholate.
8. A pharmaceutical composition for treating patients suffering from a pathogenic endobronchial microbial infection, comprising an antibacterially effective amount of monobactam compound, or a pharmaceutically acceptable salt or prodrug thereof, and an amount of a mucolytic agent effective to enhance the antibacterial activity of the monobactam compound when administered to the endobronchial space of a patient.
9. A composition of claim 8 wherein the monobactam compound is 2R 2\u03b1, 3\u03b1(Z)-3-1 (2 amino-4-thiazolyl)-2 (2 methyl 4-oxo-1 sulfo-3 azetidinyl)amino-2 oxoethylideneaminooxymethyl-6,7-dihydroxy-2-quinoxalinecarboxylic acid, aztreonam or carumonam, or a pharmaceutically acceptable salt or prodrug thereof.
10. A composition of claim 8 wherein the mucolytic agent is selected from the group consisting of N-acetyl-L-cysteine, recombinant human Dnase, Erdosteine, Gauifenesin, and sodium taurocholate.
11. A therapeutic package suitable for commercial sale for treating a patient suffering from a pathogenic endobronchial microbial infection, comprising a container, a therapeutically effective amount of an antibacterial monobactam compound, or a pharmaceutically acceptable salt or prodrug thereof, and an amount of a mucolytic agent effective to enhance the antibacterial activity of the monobactam compound in the endobronchial space of the patient.
12. A therapeutic package of claim 11 further comprising written matter instructing that the patient receive treatment with the mucolytic agent prior to treatment with the antibacterial monobactam compound.
13. A therapeutic package of claim 11 wherein the monobactam compound is 2R 2\u03b1, 3\u03b1(Z)-3-1 (2 amino-4-thiazolyl)-2 (2 methyl 4-oxo-1 sulfo-3 azetidinyl)amino-2 oxoethylideneaminooxymethyl-6,7-dihydroxy-2-quinoxalinecarboxylic acid, aztreonam or carumonam, or a pharmaceutically acceptable salt or prodrug thereof.
14. A therapeutic package of claim 13 wherein the mucolytic agent is selected from the group consisting of N-acetyl-L-cysteine, recombinant human Dnase, Erdosteine, Gauifenesin, and sodium taurocholate.
15. A therapeutic package of claim 11 further comprising a nebulizer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A curtain drawstring structure comprising:
an upper beam having a rail groove with a string hole and two inner walls on both sides of the rail groove, two projecting rails protrudingly formed at a lower portion of the two inner walls of said rail groove, and an evading space used to separate the two projecting rails, a retractable cord extending upwards through a curtain body and the string hole on the upper beam;
a fixed unit having a first upper base and a first lower base, said first lower base having a first bottom plate and two first vertical plates at a front end and a rear end respectively, wherein the two first vertical plates are provided for the first upper base to cross, and a lateral passage is formed on the fixed unit through the arrangement of the first bottom plate, two first vertical plates and the first upper base, wherein a guiding wheel and a steering wheel are pivotally disposed inside the lateral passage, and the diameter of the steering wheel is greater than that of the guiding wheel, and a standing rod with a notch is disposed on one side of the lateral passage corresponding to the steering wheel, and the other side thereof has a first extending base on each of the first vertical plates, wherein each of the first extending bases has a first stepped slot, and a first pressing bar is used in the first stepped slot; and
a movable unit having a second upper base and a second lower base, the second lower base having a second bottom plate and two second vertical plates at a front end and a rear end respectively, wherein the two second vertical plates are provided for the second upper base to cross, and a lateral passage is formed on the movable unit through the arrangement of the second bottom plate, two second vertical plates and the second upper base, wherein a guiding wheel and a steering wheel are pivotally disposed on both sides inside the lateral passage, and the diameter of the steering wheel is greater than that of the guiding wheel, and a horizontal edge is extending and formed on the second bottom plate of the movable unit, wherein a second extending base is disposed on each of the second vertical plates, and each of the second extending bases has a second stepped slot, and a second pressing bar is used in the second stepped slot, wherein a shielding piece is formed on the opposite side of the second extending base to secure a driving string, so the movable unit is connected with a string receiving unit through the driving string.
2. The curtain drawstring structure of claim 1, wherein the engagement of the first upper base and the first lower base of the fixed unit is through first hooks.
3. The curtain drawstring structure of claim 1, wherein the engagement of the second upper base and the second lower base of the movable unit is through second hooks.
4. The curtain drawstring structure of claim 1, wherein the shielding piece has a protruding unit to secure a driving string.
5. The curtain drawstring structure of claim 1, wherein the retractable cord is engaged with the fixed unit and the movable unit in the rail groove.